---
title: "Clinical trial failure of Alzheimer's drug Fosgonimeton leads to Athira Pharma plunging 72% after hours"
description: "Athira Pharma suffered a setback in clinical trials, as its Alzheimer's disease candidate drug fosgonimeton failed to meet the primary and key secondary endpoints in Phase 2/3 trials, leading to a 72%"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213392207.md"
published_at: "2024-09-04T06:35:05.000Z"
---

# Clinical trial failure of Alzheimer's drug Fosgonimeton leads to Athira Pharma plunging 72% after hours

> Athira Pharma suffered a setback in clinical trials, as its Alzheimer's disease candidate drug fosgonimeton failed to meet the primary and key secondary endpoints in Phase 2/3 trials, leading to a 72% plunge in stock price in after-hours trading. The company's Chief Medical Officer, Javier San Martin, remains optimistic about the drug's future, believing that positive modulation of the HGF pathway may improve neuronal health

According to the Zhītōng Finance APP, on Tuesday local time, Athira Pharma (ATHA.US) announced disappointing news: its candidate drug fosgonimeton for the treatment of Alzheimer's disease did not meet the primary endpoint and key secondary endpoints in a Phase 2/3 clinical trial. This result led to a significant 72% drop in the company's stock price in after-hours trading.

The study, named LIFT-AD, aimed to evaluate fosgonimeton as a potential treatment for mild to moderate Alzheimer's disease. Despite the unfavorable results, Dr. Javier San Martin, Chief Medical Officer of Athira, expressed optimism about the future in a statement. He noted that the placebo group in the trial did not show a decline in clinical symptoms, and the relatively short duration of the study may have limited the ability to fully demonstrate the therapeutic effects of fosgonimeton.

Dr. San Martin further explained, "Nevertheless, we still believe that the full dataset shows the potential for positive modulation of the HGF (hepatocyte growth factor) pathway to improve neuronal health metrics and may have a positive impact on slowing disease progression." His remarks convey the company's confidence in the drug's potential, despite the current trial results not supporting its effectiveness as a treatment for Alzheimer's disease

### Related Stocks

- [ATHA.US - Athira Pharma](https://longbridge.com/en/quote/ATHA.US.md)
- [LONA.US - LeonaBio](https://longbridge.com/en/quote/LONA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 瑞穗證券發佈了關於 LeonaBio（LONA）的正面報告 | 瑞穗證券分析師 Graig Suvannavejh 將 LeonaBio (LONA) 的評級上調至買入，目標價為 10.00 美元。Suvannavejh 專注於醫療保健領域，推薦股票的平均回報率為 20.3%，成功率為 50.00%。此 | [Link](https://longbridge.com/en/news/276278570.md) |
| LeonaBio 任命 Mark F. Kubik 為首席商務官 | LeonaBio Inc. 任命 Mark F. Kubik 為首席商務官，負責業務發展、許可、合作伙伴關係和公司事務。Kubik 曾擔任戰略顧問，並在獲得轉移性乳腺癌的 III 期 lasofoxifene 開發項目的權利方面發揮了重要作 | [Link](https://longbridge.com/en/news/274650322.md) |
| LeonaBio 宣佈特別股東大會的日期 | LeonaBio Inc. 將於 2026 年 3 月 18 日舉行虛擬特別股東會議。此公告由公共技術公司生成，僅供信息參考，不應被視為財務、投資或法律建議。原始內容通過美國證券交易委員會的 EDGAR 發佈 | [Link](https://longbridge.com/en/news/274874445.md) |
| Athira Pharma 的總法律顧問 Mark Worthington 報告了出售普通股的情況 | Athira Pharma Inc. 的總法律顧問兼首席合規官 Mark Worthington 報告了該公司普通股的處置。完整的文件可通過提供的鏈接獲取。此新聞簡報由 Public Technologies 生成，僅供參考，不應被視為財務 | [Link](https://longbridge.com/en/news/271581234.md) |
| Ascletis Pharma 在美國的口服 GLP-1 藥物二期試驗中為首批患者給藥 | Ascletis Pharma 在美國的口服 GLP-1 藥物第二階段試驗中為首批患者給藥 | [Link](https://longbridge.com/en/news/273633561.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.